Tarsus Pharmaceuticals, Inc.
TARS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001819790
In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Tarsus Pharmaceuticals, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 116 | 157 | +41 |
| Shares | 32.2M | 39.3M | +7.14M (+22.2%) |
| Value | $652.0M | $1.43B | +$777.5M (+119.3%) |
New holders (47)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (6)
Institutions that held Tarsus Pharmaceuticals, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Point72 Asset Management, L.P. | 19,575 | $396.4K |
| Bayesian Capital Management, LP | 15,400 | $311.9K |
| Oppenheimer & Co Inc | 14,056 | $284.6K |
| Mirae Asset Global Investments Co., Ltd. | 11,226 | $227.3K |
| American Century Companies Inc | 11,075 | $224.3K |
| Comerica Bank | 57 | $1.15K |